Abstract
Introduction: Both Thyroid-Hormone-Receptor alpha (TRα) 1 and 2 are processed from a gene named THRA by alternative splicing. While TRα1 holds oncogenic activity, TRα2 is suspected to act as a repressor of transcription thereby potentially antagonizing TRα1 signalling. Whether an immune-profiling of breast cancer (BC) taking into account both receptors may be of prognostic interest, remains to be unknown.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
